Latest Lynx1 Capital Management LP Stock Portfolio
Lynx1 Capital Management LP Performance:
2024 Q3: -4.73%YTD: 25.21%2023: 69.59%
Performance for 2024 Q3 is -4.73%, and YTD is 25.21%, and 2023 is 69.59%.
About Lynx1 Capital Management LP and 13F Hedge Fund Stock Holdings
Lynx1 Capital Management LP is a hedge fund based in SAN JUAN, PR. On 03-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $136.4 Millions. In it's latest 13F Holdings report, Lynx1 Capital Management LP reported an equity portfolio of $282.2 Millions as of 30 Sep, 2024.
The top stock holdings of Lynx1 Capital Management LP are MRUS, STOK, CCCC. The fund has invested 31.8% of it's portfolio in MERUS N V and 22.6% of portfolio in STOKE THERAPEUTICS INC.
The fund managers got completely rid off LONGBOARD PHARMACEUTICALS IN (LBPH), CABALETTA BIO INC (CABA) and KORRO BIO INC stocks. They significantly reduced their stock positions in PIERIS PHARMACEUTICALS INC (PIRS) and KINIKSA PHARMACEUTICALS INTL. Lynx1 Capital Management LP opened new stock positions in CARIBOU BIOSCIENCES INC (CRBU), KODIAK SCIENCES INC (KOD) and TENAX THERAPEUTICS INC (TENX). The fund showed a lot of confidence in some stocks as they added substantially to ALLOGENE THERAPEUTICS INC (ALLO), PASSAGE BIO INC (PASG) and MERUS N V (MRUS).
The top stock holdings of Lynx1 Capital Management LP are MRUS, STOK, CCCC. The fund has invested 31.8% of it's portfolio in MERUS N V and 22.6% of portfolio in STOKE THERAPEUTICS INC.
The fund managers got completely rid off LONGBOARD PHARMACEUTICALS IN (LBPH), CABALETTA BIO INC (CABA) and KORRO BIO INC stocks. They significantly reduced their stock positions in PIERIS PHARMACEUTICALS INC (PIRS) and KINIKSA PHARMACEUTICALS INTL. Lynx1 Capital Management LP opened new stock positions in CARIBOU BIOSCIENCES INC (CRBU), KODIAK SCIENCES INC (KOD) and TENAX THERAPEUTICS INC (TENX). The fund showed a lot of confidence in some stocks as they added substantially to ALLOGENE THERAPEUTICS INC (ALLO), PASSAGE BIO INC (PASG) and MERUS N V (MRUS).
Lynx1 Capital Management LP Annual Return Estimates Vs S&P 500
Our best estimate is that Lynx1 Capital Management LP made a return of -4.73% in the last quarter. In trailing 12 months, it's portfolio return was 83.27%.
New Buys
| Ticker | $ Bought |
|---|---|
| caribou biosciences inc | 1,333,170 |
| kodiak sciences inc | 707,772 |
| tenax therapeutics inc | 51,038 |
| century therapeutics inc | 32,538 |
New stocks bought by Lynx1 Capital Management LP
Additions
| Ticker | % Inc. |
|---|---|
| allogene therapeutics inc | 178 |
| passage bio inc | 66.62 |
| merus n v | 48.66 |
| cullinan therapeutics inc | 8.88 |
| gh research plc | 5.78 |
| ibio inc | 2.56 |
| stoke therapeutics inc | 0.04 |
Additions to existing portfolio by Lynx1 Capital Management LP
Reductions
| Ticker | % Reduced |
|---|---|
| pieris pharmaceuticals inc | -13.94 |
| kiniksa pharmaceuticals intl | -13.36 |
| bionomics limited | -8.34 |
Lynx1 Capital Management LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| cabaletta bio inc | -3,680,930 |
| longboard pharmaceuticals in | -4,522,580 |
| korro bio inc | -128,706 |
Lynx1 Capital Management LP got rid off the above stocks
Sector Distribution
Lynx1 Capital Management LP has about 89.9% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 89.9 |
| Others | 10.1 |
Market Cap. Distribution
Lynx1 Capital Management LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 54.4 |
| MID-CAP | 31.8 |
| UNALLOCATED | 10.1 |
| MICRO-CAP | 2.8 |
Stocks belong to which Index?
About 31.9% of the stocks held by Lynx1 Capital Management LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 68.1 |
| RUSSELL 2000 | 31.9 |
Lynx1 Capital Management LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Lynx1 Capital Management LP
Lynx1 Capital Management LP has 18 stocks in it's portfolio. About 99.2% of the portfolio is in top 10 stocks. MRUS proved to be the most loss making stock for the portfolio. CCCC was the most profitable stock for Lynx1 Capital Management LP last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ALLO | allogene therapeutics inc | 6.15 | 6,202,370 | 17,366,600 | added | 178 | ||
| CABA | cabaletta bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CCCC | c4 therapeutics inc | 13.90 | 6,880,530 | 39,219,000 | unchanged | 0.00 | ||
| CGEM | cullinan therapeutics inc | 2.44 | 410,830 | 6,877,290 | added | 8.88 | ||
| CNTA | centessa pharmaceuticals plc | 0.10 | 17,400 | 278,226 | unchanged | 0.00 | ||
| CRBU | caribou biosciences inc | 0.47 | 680,189 | 1,333,170 | new | |||
| IBIO | ibio inc | 0.68 | 862,279 | 1,914,260 | added | 2.56 | ||
| IPSC | century therapeutics inc | 0.01 | 19,028 | 32,538 | new | |||
| KOD | kodiak sciences inc | 0.25 | 271,177 | 707,772 | new | |||
| LBPH | longboard pharmaceuticals in | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MRUS | merus n v | 31.75 | 1,793,870 | 89,621,500 | added | 48.66 | ||
| PASG | passage bio inc | 2.09 | 8,426,960 | 5,898,870 | added | 66.62 | ||
| PIRS | pieris pharmaceuticals inc | 0.22 | 37,436 | 620,689 | reduced | -13.94 | ||
| STOK | stoke therapeutics inc | 22.59 | 5,187,190 | 63,750,600 | added | 0.04 | ||
| TCRX | tscan therapeutics inc | 9.22 | 5,224,600 | 26,018,500 | unchanged | 0.00 | ||
| TENX | tenax therapeutics inc | 0.02 | 14,751 | 51,038 | new | |||
| VYNE | vyne therapeutics inc | 0.01 | 16,194 | 30,445 | unchanged | 0.00 | ||
| gh research plc | 9.95 | 4,195,890 | 28,070,500 | added | 5.78 | |||
| bionomics limited | 0.09 | 549,673 | 241,471 | reduced | -8.34 | |||
| kiniksa pharmaceuticals intl | 0.07 | 8,231 | 205,693 | reduced | -13.36 | |||